Milatuzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMilatuzumab
Drug Alias Namemilatuzumabum米拉妥珠单抗米拉珠单抗Humanised anti-CD74hLL1 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD74Major histocompatibility complex II modulators
TargetsMajor histocompatibility complex IIHLA-DR antigens-associated invariant chain
Therapy Area/IndicationsGraft vs Host DiseaseLupus Erythematosus, SystemicLupus Erythematosus, Discoid +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWeill Medical College of Cornell UniversityGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseLupus Erythematosus, SystemicLupus Erythematosus, Discoid +[14] 

Other Information

ATC CodeN/A
Related LinksN/A